奥法妥木单抗与奥瑞珠单抗治疗复发型多发性硬化的比较效果:基于多国登记数据的目标试验模拟
本研究利用多国登记数据开展目标试验模拟,比较奥法妥木单抗与奥瑞珠单抗在复发型多发性硬化中的效果。两种疗法均高度有效,但奥瑞珠单抗与更低的复发率相关,奥法妥木单抗与更低的残疾进展风险相关,绝对差异显著但非常小,敏感性分析结果一致。
要点
- 奥瑞珠单抗与更低的复发率相关,奥法妥木单抗与更低的残疾进展风险相关。
- 两种药物绝对差异显著但非常小,总体临床等效。
- 差异可能源于给药频率或药物可及性不同。
核心结论
- 奥法妥木单抗与奥瑞珠单抗在复发型多发性硬化中均高度有效,总体临床等效。
- 奥瑞珠单抗与更低的复发率相关,奥法妥木单抗与更低的残疾进展风险相关,绝对差异显著但非常小。
研究设计与样本
- 基于多国登记数据的目标试验模拟,比较奥法妥木单抗与奥瑞珠单抗在复发型多发性硬化中的效果。
主要发现
- 两种疗法均显示高度有效性,但奥瑞珠单抗与更低的复发率相关,奥法妥木单抗与更低的残疾进展风险相关。
- 绝对差异显著但非常小,敏感性分析结果一致。
临床怎么用
- 研究结果支持奥瑞珠单抗与奥法妥木单抗在复发型多发性硬化中的临床等效性。
- 临床选择时需综合考虑给药频率和药物可及性对复发与残疾进展的微小差异影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing multiple sclerosis, but direct comparative evidence is limited. Prior observational studies have generally reported similar effectiveness between the two treatments, with low relapse rates and no clear differences in disability outcomes. WHAT THIS STUDY ADDS In this large real-world cohort, both therapies showed high effectiveness, but small differences were observed: ocrelizumab was associated with lower relapse rates, whereas ofatumumab was associated with a lower risk of disability progression. Absolute differences were significant but very small. Findings were consistent across sensitivity analyses. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Our findings highlight the clinical equivalence of ocrelizumab and ofatumumab. However, the small but significant divergence between relapse and disability outcomes between these drugs could be due to differences in administration frequency or drug availability,...
引用
- Journal of Neurology, Neurosurgery and Psychiatry:Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。